[go: up one dir, main page]

UA98141C2 - Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа - Google Patents

Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа

Info

Publication number
UA98141C2
UA98141C2 UAA200911452A UAA200911452A UA98141C2 UA 98141 C2 UA98141 C2 UA 98141C2 UA A200911452 A UAA200911452 A UA A200911452A UA A200911452 A UAA200911452 A UA A200911452A UA 98141 C2 UA98141 C2 UA 98141C2
Authority
UA
Ukraine
Prior art keywords
treating
quinaxoline
pi3k
inhibitors
alpha
Prior art date
Application number
UAA200911452A
Other languages
English (en)
Ukrainian (uk)
Inventor
Питер Лемб
Девид Меттьюз
Original Assignee
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экселиксис, Инк. filed Critical Экселиксис, Инк.
Publication of UA98141C2 publication Critical patent/UA98141C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение обеспечивает способы лечения рака путем введения соединения формулы Ia, возможно в виде его фармацевтически приемлемой соли, его сольвата и/или его гидрата, в комбинации с другими способами лечения рака.I
UAA200911452A 2007-04-11 2008-04-08 Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа UA98141C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11
PCT/US2008/004570 WO2008127594A2 (en) 2007-04-11 2008-04-08 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
UA98141C2 true UA98141C2 (ru) 2012-04-25

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200911452A UA98141C2 (ru) 2007-04-11 2008-04-08 Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа

Country Status (33)

Country Link
US (1) US8481001B2 (ru)
EP (1) EP2139483B9 (ru)
JP (2) JP5726515B2 (ru)
KR (1) KR101586774B1 (ru)
CN (2) CN103202842A (ru)
AU (1) AU2008239668B2 (ru)
BR (1) BRPI0810208A2 (ru)
CA (1) CA2684056A1 (ru)
CO (1) CO6140024A2 (ru)
CR (1) CR11099A (ru)
CY (1) CY1114608T1 (ru)
DK (1) DK2139483T3 (ru)
EA (1) EA019064B1 (ru)
EC (1) ECSP099723A (ru)
ES (1) ES2438998T3 (ru)
GT (1) GT200900263A (ru)
HR (1) HRP20131081T1 (ru)
IL (1) IL201211A (ru)
MA (1) MA31335B1 (ru)
ME (1) ME00937B (ru)
MX (1) MX2009010929A (ru)
MY (1) MY150797A (ru)
NI (1) NI200900184A (ru)
NZ (1) NZ580009A (ru)
PL (1) PL2139483T3 (ru)
PT (1) PT2139483E (ru)
RS (1) RS53020B (ru)
SI (1) SI2139483T1 (ru)
SV (1) SV2009003390A (ru)
TN (1) TN2009000399A1 (ru)
UA (1) UA98141C2 (ru)
WO (1) WO2008127594A2 (ru)
ZA (1) ZA200906765B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
ES2430614T3 (es) * 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
JP5687903B2 (ja) * 2008-11-10 2015-03-25 協和発酵キリン株式会社 キヌレニン産生抑制剤
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
UY33498A (es) 2010-07-09 2013-01-03 Sanofi Aventis Combinaciones de inhibidores de quinasas para el tratamiento de cancer
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
CA2815107A1 (en) 2010-10-20 2012-04-26 Merck Serono S.A. Geneva Method for preparing substituted n-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates n-(3-chloro-quinoxalin-2-yl)sulfonamides
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
IN2014CN02671A (ru) * 2011-09-14 2015-07-03 Exelixis Inc
CA2850763A1 (en) * 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
JP2014532647A (ja) * 2011-10-28 2014-12-08 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
AU2012332486A1 (en) * 2011-11-01 2014-06-19 Arthur Decillis N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
US20150010545A1 (en) * 2011-12-27 2015-01-08 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
WO2013152717A1 (zh) 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
EP2882722B1 (en) 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as gpr6 modulators
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
CN104557872B (zh) 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599196A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc COMBINATION THERAPIES FOR CANCER TREATMENT
JP5226513B2 (ja) * 2005-08-26 2013-07-03 メルク セローノ ソシエテ アノニム ピラジン誘導体及びその使用
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
EP1940839B1 (en) 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
ZA200904857B (en) 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
ES2430614T3 (es) 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
EA019064B1 (ru) 2013-12-30
WO2008127594A2 (en) 2008-10-23
EP2139483B1 (en) 2013-09-18
GT200900263A (es) 2014-01-15
PT2139483E (pt) 2013-12-27
CN101959516A (zh) 2011-01-26
CN103202842A (zh) 2013-07-17
DK2139483T3 (da) 2014-01-13
MA31335B1 (fr) 2010-04-01
BRPI0810208A2 (pt) 2014-10-21
EP2139483B9 (en) 2014-05-21
CR11099A (es) 2010-01-19
AU2008239668B2 (en) 2013-11-07
NZ580009A (en) 2012-06-29
SV2009003390A (es) 2010-05-21
CN101959516B (zh) 2013-05-08
HRP20131081T1 (hr) 2013-12-20
JP2014074031A (ja) 2014-04-24
JP5726515B2 (ja) 2015-06-03
ECSP099723A (es) 2010-03-31
IL201211A (en) 2015-09-24
EP2139483A2 (en) 2010-01-06
IL201211A0 (en) 2010-05-31
CY1114608T1 (el) 2016-10-05
MX2009010929A (es) 2010-01-20
MY150797A (en) 2014-02-28
WO2008127594A3 (en) 2009-04-30
US8481001B2 (en) 2013-07-09
HK1140141A1 (en) 2010-10-08
ES2438998T3 (es) 2014-01-21
NI200900184A (es) 2011-09-08
AU2008239668A1 (en) 2008-10-23
US20110123434A1 (en) 2011-05-26
CA2684056A1 (en) 2008-10-23
PL2139483T3 (pl) 2014-02-28
EA200970935A1 (ru) 2010-04-30
ZA200906765B (en) 2010-05-26
SI2139483T1 (sl) 2013-11-29
KR101586774B1 (ko) 2016-01-19
CO6140024A2 (es) 2010-03-19
RS53020B (sr) 2014-04-30
TN2009000399A1 (fr) 2010-12-31
KR20100019436A (ko) 2010-02-18
ME00937B (me) 2012-06-20
JP2010523669A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
TN2012000622A1 (en) Combinations of kinase inhibitors for the treatment of cancer
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
MX2009009786A (es) Inhibidores de la via de hedgehog.
TW200738725A (en) Unsaturated mTOR inhibitors
JO2886B1 (en) Useful compounds in the inhibition of CHK1
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
IN2012DN02816A (ru)
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких
UA99612C2 (en) Inhibitors of the hedgehog pathway
CY1114609T1 (el) Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας αναστολεις p13k αλφα με βαση πυριδοπυριμιδινονη
TN2011000038A1 (en) Nitrogenated derivatives of pancratistatin
DOP2009000241A (es) Inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer